Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | NDUFS8 | O00217 | 1/20 | 0.48 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.48 |
| ▸ | NDUFAB1 | O14561 | 1/20 | 0.48 |
| ▸ | NDUFA1 | O15239 | 1/20 | 0.48 |
| ▸ | NDUFS4 | O43181 | 1/20 | 0.48 |
| ▸ | NDUFB5 | O43674 | 1/20 | 0.48 |
| ▸ | NDUFB3 | O43676 | 1/20 | 0.48 |
| ▸ | NDUFC1 | O43677 | 1/20 | 0.48 |
| ▸ | NDUFA2 | O43678 | 1/20 | 0.48 |
| ▸ | NDUFS5 | O43920 | 1/20 | 0.48 |
| ▸ | NDUFS7 | O75251 | 1/20 | 0.48 |
| ▸ | NDUFS2 | O75306 | 1/20 | 0.48 |
| ▸ | NDUFS6 | O75380 | 1/20 | 0.48 |
| ▸ | NDUFB1 | O75438 | 1/20 | 0.48 |
| ▸ | NDUFS3 | O75489 | 1/20 | 0.48 |
| ▸ | NDUFB6 | O95139 | 1/20 | 0.48 |
| ▸ | NDUFA3 | O95167 | 1/20 | 0.48 |
| ▸ | NDUFB4 | O95168 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15822904 | 0.85 | KMT2A (0.50) | PTPN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4146893 | 0.84 | ALDH1A1 (0.58) | PTPN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL15822888 | 0.83 | KDM4E (0.55) | BCHEFFAR1NPC1RAB9AALDH1A1 | |
| SCHEMBL10426171 | 0.82 | MEN1 (0.71) | NPC1MAPTRAB9AKMT2AMEN1 | |
| SCHEMBL97962 | 0.81 | CA2 (0.48) | POLBNDUFS8COXFA4NDUFAB1NDUFA1 | |
| SCHEMBL3686436 | 0.80 | FFAR1 (0.59) | FFAR1KMT2AMEN1 | |
| SCHEMBL4519919 | 0.80 | MAPT (0.67) | POLBPTPN1NPC1MAPTRAB9A | |
| SCHEMBL18740250 | 0.79 | AKR1C3 (0.48) | POLBNPC1RAB9AALDH1A1TAAR1 | |
| SCHEMBL11077052 | 0.79 | ACACB (0.52) | POLBNDUFS8COXFA4NDUFAB1NDUFA1 | |
| SCHEMBL23033458 | 0.78 | BCHE (0.68) | POLBBCHEKMT2AMEN1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934594-B1 | CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES . | ALMIRALL SA (ES) | 2019-09-04 | — | — | EP | disclosed |
| CN-105142673-B | Novel cyclohexyl and quininuclidinyl carbamate derivatives with beta 2-adrenergic activator and M3 muscarinic antagonists activity | 阿尔米雷尔有限公司 | 2018-01-05 | — | — | CN | disclosed |
| US-9518050-B2 | Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity | ALMIRALL, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| CN-105142673-A | New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activity | ALMIRALL SA | 2015-12-09 | — | — | CN | disclosed |
| US-20150329535-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | ALMIRALL, S.A. (ES) | 2015-11-19 | — | — | US | disclosed |
| EP-2934594-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | Almirall, S.A. (ES) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014095920-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | ALMIRALL, S.A. (ES) | 2014-06-26 | — | — | WO | disclosed |
| EP-2426121-A1 | QUATERNARY AMMONIUM SALT COMPOUND | Teijin Pharma Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090253739-A1 | Amine Derivatives | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| EP-1999107-A2 | AMINE DERIVATIVES | Pfizer Limited (GB) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107828-A2 | AMINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329535-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | CHRM3, CHRM2, ADRB2 | POLB 2859/4885BCHE 249/4885NDUFS8 2587/4885 |
| US-20090253739-A1 | Amine Derivatives | HNMT, HRH4, CMA1 | POLB 1158/4885BCHE 794/4885NDUFS8 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.